13-06198. Miboplatin [Archived]

Nomenclature

CAS number: 103775-75-3
(SP-4-3)-[1,1-Cyclobutanedi(carboxylato-κO)(2)][(1R,2R)-2-pyrrolidinemethanamine-κN1,κN2]platinum; ()-cis-[(R)-2-(aminomethyl)pyrrolidine](1,1-cyclobutanedicarboxylato)platinum; ()-(R)-1,1-cyclobutanedicarboxylato(2-aminomethylpyrrolidine)platinum(II).
C11H18N2O4Pt; mol wt 437.36.
C 30.21%, H 4.15%, N 6.41%, O 14.63%, Pt 44.60%.

Description and references

Cytotoxic platinum complex. Prepn: M. Honda et al., EP 176005; eidem, US 4822892 (1986, 1989 both to Chugai); K. Morikawa et al., J. Pharm. Sci. 80, 837 (1991). Comparative antitumor and nephrotoxic activities of isomers: T. Matumoto et al., Br. J. Cancer 64, 41 (1991). Mechanism of action studies: M. Itoh et al., Chem. Pharm. Bull. 37, 2825 (1989); M. Akaboshi et al., Jpn. J. Cancer Res. 85, 106 (1994). Clinical evaluation: K. Tamura et al., Cancer 66, 2059 (1990). Acute toxicity: M. Suzuki et al., Yakuri to Chiryo 20, S743 (1992), C.A. 117, 124096 (1992).

Chemical structure

Derivative

Monohydrate.

Nomenclature

DWA-2114R; Neoplat (Chugai).

Properties

Colorless crystals from water, mp 248-254°. [α]D20 40.1° (c = 0.4 in water). LD50 in male, female mice, rats (mg/kg): 150, 155, 107, 135 i.v. (Suzuki).

Therapeutic Category

Antineoplastic.

Keywords

Antineoplastic; Platinum Complexes

Status

This monograph has been retired and is no longer subject to revision or update.